1. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme;Cohen;Oncologist,2009
2. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma;Friedman;J Clin Oncol,2009
3. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma;Kreisl;J Clin Oncol,2009
4. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM);Gilbert;J Clin Oncol,2013
5. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM);Wick;J Clin Oncol,2013